Target Name: MIR181C
NCBI ID: G406957
Review Report on MIR181C Target / Biomarker Content of Review Report on MIR181C Target / Biomarker
MIR181C
Other Name(s): MIRN181C | microRNA 181c | Mir-181c | hsa-miR-181c-5p | MicroRNA 181c | hsa-miR-181c-3p | mir-181c | hsa-mir-181c

MIR181C: A Potential Drug Target and Biomarker

MIR181C, also known as MIRN181C, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of certain diseases.

MIR181C is a small non-coding RNA molecule that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is composed of 249 amino acid residues and has a unique structure that consists of a long stem-loop region and a short terminal region. The stem-loop region is composed of a variable number of alternating G/C and A/T base pairs, while the terminal region has a single AUG codon that is responsible for initiating translation of the RNA molecule.

MIR181C has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival. It has also been shown to be involved in the regulation of inflammation and fibrosis. These functions make MIR181C an attractive target for drugs that are designed to interfere with its activity.

One of the potential benefits of targeting MIR181C is its potential to treat certain types of cancer. Cancer is a leading cause of death worldwide, and there is a significant need for new and more effective treatments to address this issue. MIR181C has been shown to be involved in the regulation of cell proliferation and has been shown to interact with several transcription factors that are involved in cancer development. Therefore, targeting MIR181C with drugs that inhibit its activity may have significant implications for the treatment of certain types of cancer.

Another potential application of MIR181C as a drug target is its role in the regulation of inflammation. Inflammation is a natural response of the immune system and can be a contributing factor to a variety of diseases, including cancer. MIR181C has been shown to be involved in the regulation of inflammation and has been shown to interact with several transcription factors that are involved in inflammation. Therefore, targeting MIR181C with drugs that inhibit its activity may have significant implications for the treatment of inflammatory diseases.

MIR181C has also been shown to be involved in the regulation of fibrosis, which is a condition in which tissues become abnormally thick and connective. Fibrosis can contribute to a variety of diseases, including heart failure, chronic obstructive pulmonary disease (COPD), and cancer. Therefore, targeting MIR181C with drugs that inhibit its activity may have significant implications for the treatment of fibrosis and other diseases.

In conclusion, MIR181C is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression patterns make it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of certain diseases. Further research is needed to fully understand the role of MIR181C in various cellular processes and to determine the most effective and safe methods for targeting it with drugs.

Protein Name: MicroRNA 181c

The "MIR181C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR181C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392